Pfizer Does Not Need A Merger, It Needs A Rebellion

Pfizer has many talented scientists and some of the very best R&D leaders in the industry. It also sells truly innovative drugs, such as the cancer meds Xalkori, Inlyta and Ibrance and the vaccine Prevnar. It is one of the heaviest R&D spenders in the industry, with $8.4 billion invested […]

Source: Forbes – Forbes – Management.


Published by

Shawn Boday

Shawn Boday is the CEO of Accretive Technology Group in Seattle, WA.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s